Using stimulants for attention-deficit/hyperactivity disorder: clinical approaches and challenges.
作者信息
Stevens Jonathan R, Wilens Timothy E, Stern Theodore A
出版信息
Prim Care Companion CNS Disord. 2013;15(2). doi: 10.4088/PCC.12f01472. Epub 2013 Mar 28.
Abstract
摘要
相似文献
1
Using stimulants for attention-deficit/hyperactivity disorder: clinical approaches and challenges.
Prim Care Companion CNS Disord. 2013;15(2). doi: 10.4088/PCC.12f01472. Epub 2013 Mar 28.
2
Managing attention-deficit/hyperactivity disorder in primary care: a systematic analysis of roles and challenges.
Pediatrics. 2008 Jan;121(1):e65-72. doi: 10.1542/peds.2007-0383.
3
Attention-deficit/hyperactivity disorder: etiology and pharmacotherapy.
Arch Iran Med. 2006 Oct;9(4):374-80.
4
Treatment of attention deficit/hyperactivity disorder in children with CHD.
Cardiol Young. 2021 Jun;31(6):969-972. doi: 10.1017/S1047951120004965. Epub 2021 Feb 1.
5
Predicting substance use disorder using long-term attention deficit hyperactivity disorder medication records in Truven.
Health Informatics J. 2020 Jun;26(2):787-802. doi: 10.1177/1460458219844075. Epub 2019 May 19.
6
Faking attention deficit hyperactivity disorder.
Innov Clin Neurosci. 2011 Aug;8(8):10-3.
7
Current strategies in the diagnosis and treatment of childhood attention-deficit/hyperactivity disorder.
Am Fam Physician. 2009 Apr 15;79(8):657-65.
8
Attention deficit hyperactivity disorder. Epidemiologic, pathophysiologic, diagnostic and treatment perspectives.
Saudi Med J. 2001 Aug;22(8):666-73.
9
Attention deficit hyperactivity disorder in adults: what the non-specialist needs to know.
Br J Hosp Med (Lond). 2020 Mar 2;81(3):1-11. doi: 10.12968/hmed.2019.0188. Epub 2020 Mar 16.
10
Relative benefits of stimulant therapy with OROS methylphenidate versus mixed amphetamine salts extended release in improving the driving performance of adolescent drivers with attention-deficit/hyperactivity disorder.
Pediatrics. 2006 Sep;118(3):e704-10. doi: 10.1542/peds.2005-2947.
引用本文的文献
1
Cognitive Impairment in Adult Attention Deficit Hyperactivity Disorder: Clinical Implications and Novel Treatment Strategies.
Clin Pract. 2025 Aug 12;15(8):150. doi: 10.3390/clinpract15080150.
2
Non-pharmacological Approaches to Managing Attention-Deficit Hyperactivity Disorder in Pediatric Populations: A Scoping Review.
Cureus. 2025 Jul 13;17(7):e87810. doi: 10.7759/cureus.87810. eCollection 2025 Jul.
3
Prevalence Trends and Patterns of Perinatal ADHD Stimulant Medication Use in British Columbia, Canada.
Pharmacoepidemiol Drug Saf. 2025 Apr;34(4):e70129. doi: 10.1002/pds.70129.
4
Neuroimaging as a Tool for Advancing Pediatric Psychopharmacology.
Paediatr Drugs. 2025 May;27(3):307-330. doi: 10.1007/s40272-025-00683-9. Epub 2025 Feb 3.
5
Stimulant medications effects in heat-related illness in ADHD patients: a large database study.
Front Psychiatry. 2024 Dec 20;15:1509385. doi: 10.3389/fpsyt.2024.1509385. eCollection 2024.
6
Prevalence and correlates of common mental disorders among participants of the Uganda Genome Resource: Opportunities for psychiatric genetics research.
Mol Psychiatry. 2025 Jan;30(1):122-130. doi: 10.1038/s41380-024-02665-8. Epub 2024 Jul 14.
7
Impact of COVID-19 pandemic on prescription stimulant use among children and youth: a population-based study.
Eur Child Adolesc Psychiatry. 2024 Aug;33(8):2669-2680. doi: 10.1007/s00787-023-02346-x. Epub 2024 Jan 5.
8
The Role of Alpha-2 Agonists for Attention Deficit Hyperactivity Disorder in Children: A Review.
Neurol Int. 2023 May 22;15(2):697-707. doi: 10.3390/neurolint15020043.
9
Double-Blind, Sham-Controlled Randomized Trial Testing the Efficacy of fMRI Neurofeedback on Clinical and Cognitive Measures in Children With ADHD.
Am J Psychiatry. 2022 Dec 1;179(12):947-958. doi: 10.1176/appi.ajp.21100999. Epub 2022 Nov 9.
10
Patterns of Medication Prescription among Children and Adolescents with Attention-Deficit/Hyperactivity Disorder in the United States.
Children (Basel). 2022 Jan 30;9(2):171. doi: 10.3390/children9020171.
本文引用的文献
1
Medication use in US youth with mental disorders.
JAMA Pediatr. 2013 Feb;167(2):141-8. doi: 10.1001/jamapediatrics.2013.431.
2
ADHD drugs and serious cardiovascular events in children and young adults.
N Engl J Med. 2011 Nov 17;365(20):1896-904. doi: 10.1056/NEJMoa1110212. Epub 2011 Nov 1.
3
Cardiovascular risk of stimulant treatment in pediatric attention-deficit/hyperactivity disorder: update and clinical recommendations.
J Am Acad Child Adolesc Psychiatry. 2011 Oct;50(10):978-90. doi: 10.1016/j.jaac.2011.07.018. Epub 2011 Sep 3.
4
Adaptive phase I study of OROS methylphenidate treatment of attention deficit hyperactivity disorder with epilepsy.
Epilepsy Behav. 2010 Jul;18(3):229-37. doi: 10.1016/j.yebeh.2010.02.022. Epub 2010 May 21.
5
A controlled trial of the methylphenidate transdermal system on before-school functioning in children with attention-deficit/hyperactivity disorder.
J Clin Psychiatry. 2010 May;71(5):548-56. doi: 10.4088/JCP.09m05779pur.
6
Plasma methylphenidate concentrations in youths treated with high-dose osmotic release oral system formulation.
J Child Adolesc Psychopharmacol. 2010 Feb;20(1):49-54. doi: 10.1089/cap.2008.0128.
7
Prevalence and treatment of mental disorders among US children in the 2001-2004 NHANES.
Pediatrics. 2010 Jan;125(1):75-81. doi: 10.1542/peds.2008-2598. Epub 2009 Dec 14.
8
Do stimulants protect against psychiatric disorders in youth with ADHD? A 10-year follow-up study.
Pediatrics. 2009 Jul;124(1):71-8. doi: 10.1542/peds.2008-3347.
9
Sudden death and use of stimulant medications in youths.
Am J Psychiatry. 2009 Sep;166(9):992-1001. doi: 10.1176/appi.ajp.2009.09040472. Epub 2009 Jun 15.
10
Absence of cytogenetic effects in children and adults with attention-deficit/hyperactivity disorder treated with methylphenidate.
Mutat Res. 2009 Jun 18;666(1-2):44-9. doi: 10.1016/j.mrfmmm.2009.03.014. Epub 2009 Apr 9.
Zotero 插件